Monoclonal immunoglobulin (Ig) light chain amyloidosis (AL) is a rare but severe disease
that may occur when a B or plasma cell clone secretes an excess of free Ig light chains …

The adaptive immune system of jawed vertebrates generates a highly diverse repertoire of
antibodies to meet the antigenic challenges of a constantly evolving biological ecosystem …

The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …

Machine learning has been recently used to predict therapeutic antibody aggregation rates
and viscosity at high concentrations (150 mg/ml). These works focused on commercially …

Solid ashes constitute the world's leading environmental problem and their efficient
recycling requires specific origin information. Chemical signatures encode the …

Background Systemic AL amyloidosis arises from the misfolding of patient-specific
immunoglobulin light chains (LCs). Potential drivers of LC amyloid formation are mutational …

To the Editor: Each patient with a monoclonal gammopathy has a unique monoclonal (M)
protein, whose sequence can be used as a tumoral fingerprint to track the presence of the B …

Immunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder
characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril …

Cardiac amyloidosis (CA) is an underdiagnosed form of infiltrative cardiomyopathy caused
by abnormal amyloid fibrils deposited extracellularly in the myocardium and cardiac …

Over 120 FDA-approved antibody-based therapeutics are used to treat a variety of diseases.
However, many candidates could fail because of unfavorable physicochemical properties …